BACKGROUND: Cardiovascular disease is one of the main causes of mortality in patients with chronic obstructive pulmonary disease (COPD), and atherosclerosis is a cause of cardiac comorbidities in COPD. However, it is not clear whether airflow limitation is associated with atherosclerosis irrespective of smoking. OBJECTIVE: To investigate whether airflow limitation is independently associated with vascular stiffness. METHODS: We enrolled 18 893 participants (male 70.5%; mean age 47.5 6 9.8 years; never smokers 44.2%) who underwent spirometry and brachial-ankle pulse wave velocity (baPWV) as part of a standard health examination at Ajou University Hospital, Suwon, South Korea, from January 2010 to December 2015. We defined vascular peripheral atherosclerosis as baPWV ≥ 1400 cm/s and airflow limitation as prebronchodilator ratio of forced expiratory volume in 1 sec (FEV1) to forced vital capacity (FVC),70%. RESULTS: Mean baPWV was higher in subjects with airflow limitation (1477.6 6 331.7 cm/sec, n ¼ 638) than in those without airflow limitation (1344.1 6 231.8 cm/sec, n ¼ 18255, P, 0.001). In multivariate logistic regression analysis, the following were independent predictors associated with peripheral atherosclerosis (P, 0.05): age, male sex, fasting serum glucose, mean blood pressure, serum leukocyte count, serum low density lipoprotein level and FEV1. CONCLUSION: Airflow limitation was an independent predictor of vascular stiffness irrespective of smoking history, which suggests that airflow limitation is linked with atherosclerosis.
|Number of pages||8|
|Journal||International Journal of Tuberculosis and Lung Disease|
|Publication status||Published - 2020 Jun 1|
Bibliographical noteFunding Information:
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Chungcheongbuk-do, South Korea, funded by the Ministry of Health & Welfare, Seoul, Republic of Korea (grant number : HI16C0992) Conflicts of interest: DS reports grants and personal fees from Apellis (Waltham, MA, USA), AstraZeneca (Cambridge, UK), Boehringer Ingleheim (Ingelheim am Rhein, Germany), Chiesi (Parma, Italy), Cipla (Mumbai, India), Glenmark (Mumbai, India), Merck (Kenilworth, NJ, USA), Mundipharma (Cambridge, UK), Novartis (Basel, Switzerland), Peptinnovate (Stevenage, UK), Pfizer (New York, NY, USA), Pulmatrix (Lexington, MA, USA), Teva (Petah Tikva, Israel), Therevance (South San Francisco, CA, USA) and Verona (London, UK), and personal fees from Genentech (South San Francisco, CA, USA) and Skyepharma (London, UK) outside the submitted work. Other authors have nothing to declare. Declaration: Data for this study will be provided on request.
© 2020 The Union.
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine
- Infectious Diseases